Evidence map›Paper›PMID 38457748›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer.

Yohei Ando, Mohamad Dbouk, Takeichi Yoshida, Helena Saba, Elizabeth Abou Diwan, Kanako Yoshida, Ali Dbouk, Amanda L Blackford, Ming-Tseh Lin, Anne Marie Lennon and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Observational
  3. Article
  4. Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  5. Catching pancreatic cancer early: Are we there yet?Journal of the National Cancer Center · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Personalizing CA125 Levels Using Tumor Marker Variants: A Case-Control Analysis of Diagnostic Performance for Pancreatic Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Yohei AndoDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.ORCID 0009-0002-4005-038X
Mohamad DboukDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.ORCID 0000-0002-6055-0202
Takeichi YoshidaDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.
Helena SabaDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.ORCID 0009-0004-0973-9116
Elizabeth Abou DiwanDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.ORCID 0009-0007-4264-9982
Kanako YoshidaDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.
Ali DboukDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.ORCID 0009-0001-0566-141X
Amanda L BlackfordDepartment of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.ORCID 0000-0002-6519-4833
Ming-Tseh LinDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.
Anne Marie LennonDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.ORCID 0000-0001-8957-3945
Richard A BurkhartDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.
Jin HeDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.ORCID 0000-0001-9149-2247
Lori SokollDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.
James R EshlemanDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.ORCID 0000-0002-9274-8459
Marcia Irene CantoDepartment of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.ORCID 0000-0002-2193-3032
Michael GogginsDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.ORCID 0000-0002-4286-2296
Johns Hopkins University · US

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
Using markers to improve pancreatic cancer screening and surveillance: a multi-center studyU01CA210170 · NCI · JOHNS HOPKINS UNIVERSITY · PI Michael G. Goggins · 2016 to 2026
$9.3M
Using Markers to Improve Pancreatic Cancer ScreeningR01CA176828 · NCI · JOHNS HOPKINS UNIVERSITY · PI GOGGINS, MICHAEL G. · 2013 to 2024
$4.1M
NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA176828NCI NIH HHS U01 CA210170
6 · The paper itself

Abstract

purposeCirculating carbohydrate antigen 19-9 (CA19-9) levels reflect FUT3 and FUT2 fucosyltransferase activity. Measuring the related glycan, DUPAN-2, can be useful in individuals unable to synthesize CA19-9. We hypothesized that similar to CA19-9, FUT functional groups determined by variants in MATERIALS AND

methodsUsing a training/validation study design,

resultsIn controls, three functional FUT groups were identified with significant differences in DUPAN-2 levels: FUT3-intact, FUT3-null/FUT2-intact, and FUT3-null/FUT2-null. DUPAN-2 training set diagnostic cutoffs for each FUT group yielded higher diagnostic sensitivity in the validation set for patients with stage I/II PDAC than uniform cutoffs (60.4% [95% CI, 50.2 to 70.0]

conclusionUsing a tumor marker gene test to individualize CA19-9 and DUPAN-2 reference ranges achieves high diagnostic performance for stage I/II pancreatic cancer.

Indexed as

Biomarkers, TumorCA-19-9 AntigenCarcinoma, Pancreatic DuctalFucosyltransferasesGalactoside 2-alpha-L-fucosyltransferasePancreatic NeoplasmsAgedAntigens, NeoplasmFemaleGenotypeHumansMaleMiddle AgedSensitivity and Specificity3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferaseAntigens, NeoplasmBiomarkers, TumorCA-19-9 AntigenDU-PAN-2 antigen, humanFucosyltransferasesGalactoside 2-alpha-L-fucosyltransferase

Identifiers

PMID38457748
PMCPMC11191066
OpenAlexW4392616415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.